• Fund Type: SICAV
  • Objective: Health Care Sector
  • Asset Class: Equity
  • Geographic Focus: International

Dexia Equities L - Biotechnology

+ Add to Watchlist

DEXEBTN:LX

271.26 USD 6.13 2.31%

As of 00:59:30 ET on 04/16/2014.

Snapshot for Dexia Equities L - Biotechnology (DEXEBTN)

Year To Date: -3.67% 3-Month: -10.77% 3-Year: +24.89% 52-Week Range: 211.75 - 335.17
1-Month: -13.95% 1-Year: +25.97% 5-Year: +31.08% Beta vs BTK: 0.89

Mutual Fund Chart for DEXEBTN

No chart data available.
  • DEXEBTN:LX 271.26
  • 1M
  • 1Y
Interactive DEXEBTN Chart

Previous Close

No chart data available.
Interactive Chart
  • 1W
  • 1M
  • YTD
  • 1Y
  • 3Y
  • 5Y
Close:
Open:
High:
Low:
Volume:
Recently Viewed Symbols
Save as Watchlist
Saving as watchlist...

Fund Profile & Information for DEXEBTN

Dexia Equities L - Biotechnology is a SICAV incorporated under the laws of Luxembourg. The Fund's objective is capital appreciation. The Fund invests in global biotechnology stocks. Because the sector is currently experiencing the highest growth in the U.S., at least two-thirds of the Fund's assets will be invested in U.S. biotechnology stocks.

Inception Date: 08-23-2002 Telephone: 352-254-3431
Managers: RUDI VAN DEN EYNDE
Web Site: www.candriam.com

Fundamentals for DEXEBTN

NAV (on 2014-04-16) 271.26
Assets (M) (on 2014-04-16) 550.41
Fund Leveraged N
Minimum Investment -
Minimum Subsequent Investment -

Dividends for DEXEBTN

No dividends reported

Fees & Expenses for DEXEBTN

Front Load 0.00
Back Load 0.00
Current Mgmt Fee 2.00
Redemption Fee 0.00
12b1 Fee -
Expense Ratio 2.23

Top Fund Holdings for DEXEBTN

Filing Date: 07/31/2013
Name Position Value % of Total
Celgene Corp 261,000 38,330,460 7.753%
Gilead Sciences Inc 594,000 36,501,300 7.383%
Biogen Idec Inc 163,000 35,555,190 7.192%
Amgen Inc 308,000 33,353,320 6.747%
Regeneron Pharmaceuticals Inc 90,000 24,305,400 4.916%
Alexion Pharmaceuticals Inc 150,000 17,434,500 3.527%
Vertex Pharmaceuticals Inc 160,000 12,768,000 2.583%
H Lundbeck A/S 608,000 12,236,869 2.475%
Trius Therapeutics Inc 570,000 8,036,943 1.626%
BioMarin Pharmaceutical Inc 123,000 7,951,950 1.609%

Quotes delayed, except where indicated otherwise. Mutual fund NAVs include dividends. All prices in local currency. Time is ET.

Advertisement
Advertisement
Sponsored Links
Advertisements
sec ||= nil